Dr Krina K. Patel is an associate professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, and was previously in the Department of Stem Cell Transplantation, at the University of Texas MD Anderson Cancer Center (UT MDACC) in Houston Texas. She earned her bachelor’s degree at the University of Pennsylvania, medical degree from the University of Texas Southwestern Medical Center, Dallas and completed a fellowship in hematology-oncology at UT MDACC where she served as Chief fellow for 2 years and completed her Master of Science in the lab of Laurence Cooper MD PHD evaluating the combination of NY-ESO-1 T-APC vaccine with TCR in Multiple Myeloma cell line and mouse models. She currently serves as the Center Medical Director and Service Line Leader for her department.
Dr Patel’s research focus is on improving therapy and outcomes for patients with MM and other plasma cell dyscrasias. Her specific research interests include improving survival and quality of life
for patients with MM, POEMS, and plasmablastic lymphoma, using cellular therapy such as chimeric antigen receptor T cells with or without transplant and combining immunotherapy in the
induction, transplant, maintenance, and salvage settings. She has acted as principal investigator on several MM clinical trials with a focus on immunotherapies such as novel CAR T, monoclonal
antibodies, cytokines, and vaccine studies. She is also currently co-PI for a translational study evaluating ctDNA and scRNAseq data for patients undergoing standard of care CAR T studies.
Outside of her clinical and translational interests, Dr. Patel is dedicated to improving outcomes and access to these novel therapies for vulnerable patient populations such as minority patient groups and those with high risk disease.
Dr Patel is a member of ASH, ASCO, ASGCT, AACR, and ASTCT. Her research has been published in numerous peer-reviewed journals.